Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

(750) (2,151) Research and development expenses. (74,281) (48,278) Administrative and selling expenses (11,358) (11,322) Other income 3,814 3,933 Operating loss (79,213) (37,198) Net financial income 5,458 5,183 Loss before income tax (73,755) (32,015) Income tax expense (132) (129) Loss for the period (73,887) (32,144) Attributable to: - Equity holders of the Company (73,887) (32,144) - minority interests - - Earnings per share for profit attributable to equity holders of the Company (1.56) (0.69) Diluted (1.56) (0.69) CONSOLIDATED BALANCE SHEET December 31, 2008 December 31, 2007 (in thousands of EUR) ASSETS Non current assets Property, plant, & 3,429 2,720 equipment Intangible 835 464 assets Financial instruments 4,858 14,402 Government subsidies receivable - 5,264 Other financial assets 201 186 Deferred income tax assets 21 10 Total non-current 9,344 23,046 assets Current assets Financial assets 396 - Trade receivables
'/>"/>
SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Israel Biomedical Sensors Market - Growth, ... The Israel Biomedical Sensors market is ... of 3.73% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/31/2015)... 31, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... is pleased to announce that its wholly owned subsidiary, ... candidate, PPL-003, to an Investigational New Drug (IND) application ... uveitis.  PPL recently completed a study in a rat ... achieved highly significant efficacy and a more rapid onset ...
(Date:8/31/2015)... HAYWARD, Calif. and SHANGHAI ... Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, ... Phase 2 clinical study for its lead drug ... designed to treat drug-resistant bacteria such as MRSA ... safer and better tolerated therapeutic option than currently ...
(Date:8/31/2015)... 31, 2015 Trimb Healthcare AB ("Trimb") today ... YouMedical Group BV ("YouMedical"), a Dutch OTC company with ... sales of approximately EUR 16 million, with solid growth ... "Our ambition is to build a leading international OTC ... that goal. YouMedical gives us a stronger North European ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... movies of living cell membranes, taken by a research ... New Mexico, have clarified a decades-old enigma surrounding receptor ... of the Journal of Cell Biology , promise ... development. The work focuses on G protein-coupled receptors ...
... Feb. 7, 2011 Gizmox, the developer of ... their entrance into the Business Mobility Market. Visual WebGui,s ... applications to the Web or Cloud, has now been ... using a simple mapping and configuration tool.  IdeoMobile, in ...
... 2011 Cmed Technology ... host a roundtable and give a presentation about electronic ... Summit for Clinical Ops Executives ( SCOPE ) conference ... (Logo: http://photos.prnewswire.com/prnh/20100707/NY31446LOGO) As part of SCOPE,s two-day ...
Cached Biology Technology:Expanding drug development horizons: Receptor behaviors observed in living cell membranes 2Gizmox Enters the Business Mobile Application Market - Visual WebGui Based Solutions Deployed in Major Financial and Medical Institutions 2Gizmox Enters the Business Mobile Application Market - Visual WebGui Based Solutions Deployed in Major Financial and Medical Institutions 3Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 2Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 3
(Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... follows form" might have been written to describe proteins, ... nature,s workhorse biomolecules enables each to carry out its ... X-ray protein crystallography, in which a beam of x-rays ... protein,s atoms, creating a diffraction pattern of dots that ...
... prescribed drugs for the treatment of heart failure are beta-blockers ... the heart,s workload. The drugs were thought to produce those ... study led by scientists at Temple University School of Medicine, ... counteracting the effects of an enzyme known as GRK2. The ...
... Nov. 5, 2013  The AVS has selected its major award ... to encourage excellence in research and innovation in technical areas ... award winners: Medard W. Welch Award— Dr. ... Barbara, "For seminal contributions to the theory of heterojunctions and ...
Cached Biology News:Bringing out the best in X-ray crystallography data 2Temple researchers uncover clues to how existing heart drugs work 2AVS Announces Its Major Award Winners of 2013 2AVS Announces Its Major Award Winners of 2013 3AVS Announces Its Major Award Winners of 2013 4AVS Announces Its Major Award Winners of 2013 5AVS Announces Its Major Award Winners of 2013 6
... Antibody to Cytokeratin 5 / 6 ... molecular weight, basic type of cytokeratin expressed ... cell layers of stratified epithelia as well ... mesothelial cells and mesothelioma. Cytokeratin 6 (56 ...
Aldolase A (N-15)...
... Y2 Receptor antiserum This NPY Y2 ... level and is currently being characerized in brain. ... and mouse and appears to work better on ... rat. For full characterizarion in dorsal root ganglion ...
Black Polypropylene 384 Round Well Plate 70/Box...
Biology Products: